Publications in collaboration with researchers from University of Münster (15)

2011

  1. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trial

    British Journal of Haematology, Vol. 153, Núm. 2, pp. 212-221

  2. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma

    European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384

  3. Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

    Oncologist, Vol. 16, Núm. 4, pp. 388-403

  4. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study

    European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31

  5. Treatment of relapsed and refractory multiple myeloma in the era of novel agents

    Cancer Treatment Reviews, Vol. 37, Núm. 4, pp. 266-283

2010

  1. Current multiple myeloma treatment strategies with novel agents: A European perspective

    Oncologist, Vol. 15, Núm. 1, pp. 6-25

  2. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

    Blood, Vol. 116, Núm. 19, pp. 3743-3750

  3. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

    The Lancet Oncology, Vol. 11, Núm. 11, pp. 1086-1095

2009

  1. A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP

    CLINICAL LYMPHOMA & MYELOMA

  2. Bortezomib and Melphalan as Part of VMP Are Associated with Similar Hematologic Toxicity to MP Alone

    CLINICAL LYMPHOMA & MYELOMA

  3. Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

    CLINICAL LYMPHOMA & MYELOMA

  4. Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

    CLINICAL LYMPHOMA & MYELOMA

  5. VMP Results in Fewer Bone Events and Greater ALP Increases Versus MP in the VISTA Study in Front-Line MM

    CLINICAL LYMPHOMA & MYELOMA

  6. VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study

    CLINICAL LYMPHOMA & MYELOMA

2008

  1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

    New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917